---
document_datetime: 2025-12-02 05:10:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/blenrep1.html
document_name: blenrep1.html
version: success
processing_time: 0.1102757
conversion_datetime: 2025-12-26 10:29:08.184304
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Blenrep

[RSS](/en/individual-human-medicine.xml/67341)

##### Expired

This medicine's authorisation has expired

belantamab mafodotin Medicine Human Expired

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Blenrep](#news-on)
- [More information on Blenrep](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 23 February 2024, the European Commission issued a decision to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) in the European Union (EU). The marketing authorisation holder for the medicine was GlaxoSmithKline (Ireland) Limited.

The non-renewal of the marketing authorisation follows the opinion issued by EMA's human medicines committee, CHMP, which recommended to not renew the authorisation because the benefits of Blenrep no longer outweigh its risks.

Further information is available in the [news announcement](/node/183444) published at the time of the CHMP opinion.

Blenrep was granted a conditional marketing authorisation valid throughout the EU on 25 August 2020 for the treatment of multiple myeloma.

The European Public Assessment Report (EPAR) for Blenrep has been updated to indicate that the marketing authorisation is no longer valid.

Blenrep : EPAR - Medicine overview

Reference Number: EMA/407643/2020

English (EN) (206.74 KB - PDF)

**First published:** 17/09/2020

**Last updated:** 13/03/2024

[View](/en/documents/overview/blenrep-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-844)

български (BG) (234.39 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/bg/documents/overview/blenrep-epar-medicine-overview_bg.pdf)

español (ES) (205.5 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/es/documents/overview/blenrep-epar-medicine-overview_es.pdf)

čeština (CS) (247.94 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/cs/documents/overview/blenrep-epar-medicine-overview_cs.pdf)

dansk (DA) (200.3 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/da/documents/overview/blenrep-epar-medicine-overview_da.pdf)

Deutsch (DE) (212.35 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/de/documents/overview/blenrep-epar-medicine-overview_de.pdf)

eesti keel (ET) (183.71 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/et/documents/overview/blenrep-epar-medicine-overview_et.pdf)

ελληνικά (EL) (283.85 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/el/documents/overview/blenrep-epar-medicine-overview_el.pdf)

français (FR) (207.67 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/fr/documents/overview/blenrep-epar-medicine-overview_fr.pdf)

hrvatski (HR) (239.75 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/hr/documents/overview/blenrep-epar-medicine-overview_hr.pdf)

italiano (IT) (203.37 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/it/documents/overview/blenrep-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (259.49 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/lv/documents/overview/blenrep-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (248.05 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/lt/documents/overview/blenrep-epar-medicine-overview_lt.pdf)

magyar (HU) (241.88 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/hu/documents/overview/blenrep-epar-medicine-overview_hu.pdf)

Malti (MT) (258.79 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/mt/documents/overview/blenrep-epar-medicine-overview_mt.pdf)

Nederlands (NL) (207.71 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/nl/documents/overview/blenrep-epar-medicine-overview_nl.pdf)

polski (PL) (247.35 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/pl/documents/overview/blenrep-epar-medicine-overview_pl.pdf)

português (PT) (206.8 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/pt/documents/overview/blenrep-epar-medicine-overview_pt.pdf)

română (RO) (250.38 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/ro/documents/overview/blenrep-epar-medicine-overview_ro.pdf)

slovenčina (SK) (249.5 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sk/documents/overview/blenrep-epar-medicine-overview_sk.pdf)

slovenščina (SL) (240.87 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sl/documents/overview/blenrep-epar-medicine-overview_sl.pdf)

Suomi (FI) (198.98 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/fi/documents/overview/blenrep-epar-medicine-overview_fi.pdf)

svenska (SV) (202.28 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sv/documents/overview/blenrep-epar-medicine-overview_sv.pdf)

Blenrep : EPAR - Risk Management Plan

English (EN) (50 MB - PDF)

**First published:** 25/10/2023

**Last updated:** 13/03/2024

[View](/en/documents/rmp/blenrep-epar-risk-management-plan_en.pdf)

## Product information

Blenrep : EPAR - Product information (no longer authorised)

English (EN) (1.6 MB - PDF)

**First published:** 17/09/2020

**Last updated:** 13/03/2024

[View](/en/documents/product-information/blenrep-epar-product-information-no-longer-authorised_en.pdf)

[Other languages (24)](#file-language-dropdown-313)

български (BG) (1.97 MB - PDF)

**First published:**

21/10/2025

[View](/bg/documents/product-information/blenrep-epar-product-information_1-bg.pdf)

español (ES) (1.54 MB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/es/documents/product-information/blenrep-epar-product-information_es.pdf)

čeština (CS) (1.74 MB - PDF)

**First published:**

21/10/2025

[View](/cs/documents/product-information/blenrep-epar-product-information_1-cs.pdf)

dansk (DA) (1.5 MB - PDF)

**First published:**

21/10/2025

[View](/da/documents/product-information/blenrep-epar-product-information_1-da.pdf)

Deutsch (DE) (1.62 MB - PDF)

**First published:**

21/10/2025

[View](/de/documents/product-information/blenrep-epar-product-information_1-de.pdf)

eesti keel (ET) (1.62 MB - PDF)

**First published:**

21/10/2025

[View](/et/documents/product-information/blenrep-epar-product-information_1-et.pdf)

ελληνικά (EL) (2.61 MB - PDF)

**First published:**

21/10/2025

[View](/el/documents/product-information/blenrep-epar-product-information_1-el.pdf)

français (FR) (1.76 MB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/fr/documents/product-information/blenrep-epar-product-information_fr.pdf)

hrvatski (HR) (1.75 MB - PDF)

**First published:**

21/10/2025

[View](/hr/documents/product-information/blenrep-epar-product-information_1-hr.pdf)

íslenska (IS) (1.46 MB - PDF)

**First published:**

21/10/2025

[View](/is/documents/product-information/blenrep-epar-product-information_1-is.pdf)

italiano (IT) (1.69 MB - PDF)

**First published:**

21/10/2025

[View](/it/documents/product-information/blenrep-epar-product-information_1-it.pdf)

latviešu valoda (LV) (1.78 MB - PDF)

**First published:**

21/10/2025

[View](/lv/documents/product-information/blenrep-epar-product-information_1-lv.pdf)

lietuvių kalba (LT) (1.8 MB - PDF)

**First published:**

21/10/2025

[View](/lt/documents/product-information/blenrep-epar-product-information_1-lt.pdf)

magyar (HU) (1.9 MB - PDF)

**First published:**

21/10/2025

[View](/hu/documents/product-information/blenrep-epar-product-information_1-hu.pdf)

Malti (MT) (2.03 MB - PDF)

**First published:**

21/10/2025

[View](/mt/documents/product-information/blenrep-epar-product-information_1-mt.pdf)

Nederlands (NL) (1.73 MB - PDF)

**First published:**

21/10/2025

[View](/nl/documents/product-information/blenrep-epar-product-information_1-nl.pdf)

norsk (NO) (1.51 MB - PDF)

**First published:**

21/10/2025

[View](/no/documents/product-information/blenrep-epar-product-information_1-no.pdf)

polski (PL) (1.85 MB - PDF)

**First published:**

21/10/2025

[View](/pl/documents/product-information/blenrep-epar-product-information_1-pl.pdf)

português (PT) (1.51 MB - PDF)

**First published:**

21/10/2025

[View](/pt/documents/product-information/blenrep-epar-product-information_1-pt.pdf)

română (RO) (1.91 MB - PDF)

**First published:**

21/10/2025

[View](/ro/documents/product-information/blenrep-epar-product-information_1-ro.pdf)

slovenčina (SK) (1.95 MB - PDF)

**First published:**

21/10/2025

[View](/sk/documents/product-information/blenrep-epar-product-information_1-sk.pdf)

slovenščina (SL) (1.74 MB - PDF)

**First published:**

21/10/2025

[View](/sl/documents/product-information/blenrep-epar-product-information_1-sl.pdf)

Suomi (FI) (1.53 MB - PDF)

**First published:**

21/10/2025

[View](/fi/documents/product-information/blenrep-epar-product-information_1-fi.pdf)

svenska (SV) (1.56 MB - PDF)

**First published:**

21/10/2025

[View](/sv/documents/product-information/blenrep-epar-product-information_1-sv.pdf)

**Latest procedure affecting product information:** R/017 23/02/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Blenrep : EPAR - All authorised presentations

English (EN) (42.5 KB - PDF)

**First published:** 17/09/2020

**Last updated:** 13/03/2024

[View](/en/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-633)

български (BG) (76.86 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/bg/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_bg.pdf)

español (ES) (89.85 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/es/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.22 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/cs/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (51.08 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/da/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (51.01 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/de/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.62 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/et/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.08 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/el/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_el.pdf)

français (FR) (72.85 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/fr/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.47 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/hr/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (92.79 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/is/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_is.pdf)

italiano (IT) (66.89 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/it/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.96 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/lv/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (76.51 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/lt/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (93.53 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/hu/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (81.16 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/mt/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (67.27 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/nl/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (77.86 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/no/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.04 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/pl/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_pl.pdf)

português (PT) (77.12 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/pt/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_pt.pdf)

română (RO) (77.97 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/ro/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (80.92 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sk/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (76.87 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sl/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (72.89 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/fi/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (75.04 KB - PDF)

**First published:**

17/09/2020

**Last updated:**

13/03/2024

[View](/sv/documents/all-authorised-presentations/blenrep-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Blenrep Active substance belantamab mafodotin International non-proprietary name (INN) or common name belantamab mafodotin Therapeutic area (MeSH) Multiple Myeloma Anatomical therapeutic chemical (ATC) code L01XC39

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

## Authorisation details

EMA product number EMEA/H/C/004935

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 23/07/2020 Marketing authorisation issued 25/08/2020 Expiry of marketing authorisation 23/02/2024 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Blenrep : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (395.71 KB - PDF)

**First published:** 29/01/2021

**Last updated:** 13/03/2024

[View](/en/documents/procedural-steps-after/blenrep-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Blenrep-H-C-004935-R-0017 : EPAR - Assessment Report - Renewal

Reference Number: EMA/72045/2024

English (EN) (7.03 MB - PDF)

**First published:** 04/03/2024

**Last updated:** 13/03/2024

[View](/en/documents/variation-report/blenrep-h-c-004935-r-0017-epar-assessment-report-renewal_en.pdf)

Blenrep-H-C-PSUSA-00010869-202208 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/264790/2023

English (EN) (171.09 KB - PDF)

**First published:** 09/06/2023

**Last updated:** 13/03/2024

[View](/en/documents/scientific-conclusion/blenrep-h-c-psusa-00010869-202208-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Blenrep : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-499024

English (EN) (650.47 KB - PDF)

**First published:** 17/09/2020

**Last updated:** 13/03/2024

[View](/en/documents/orphan-maintenance-report/blenrep-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Blenrep : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/414341/2020 Corr.

English (EN) (8.78 MB - PDF)

**First published:** 17/09/2020

**Last updated:** 13/03/2024

[View](/en/documents/assessment-report/blenrep-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Blenrep

Adopted

Reference Number: EMA/383350/2020

English (EN) (168.98 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-blenrep_en.pdf)

#### News on Blenrep

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023) 15/12/2023

[EMA confirms recommendation for non-renewal of authorisation of multiple myeloma medicine Blenrep](/en/news/ema-confirms-recommendation-non-renewal-authorisation-multiple-myeloma-medicine-blenrep) 15/12/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

[EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep](/en/news/ema-recommends-non-renewal-authorisation-multiple-myeloma-medicine-blenrep) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

[First antibody-drug conjugate for multiple myeloma patients with limited treatment options](/en/news/first-antibody-drug-conjugate-multiple-myeloma-patients-limited-treatment-options) 24/07/2020

#### More information on Blenrep

- [BLENREP Effectiveness and Safety in Multiple Myeloma (BEaMM) - Real-World Evidence on Patients Taking Belantamab Mafodotin in Europe (217240) - post-authorisation study](https://catalogues.ema.europa.eu/study/49148)

**This page was last updated on** 19/02/2025

## Share this page

[Back to top](#main-content)